

2016' VHRC 2nd Int. Symposium

Understanding of Vulnerable Blood with Blood Rheology





Sehyun Shin Ph.D.
Professor, Korea University
Director, nano-Biofluid Diagnostic ERC

Vulnerable Plaque

Atherosclerotic cardiovascular disease :

- a major cause of sudden deaths for several decades
- CAD is the most directly correlated with the results





Unanswered Questions:

1. Plaque is going to be ruptured soon or not ?
2. Plaque rupture leads to occlusive thrombosis ?
3. How the clots would be lysed ?

Unsolved Puzzles in CVDs

Is it due to vulnerable plaque or vulnerable blood ?



Hemodynamics


In-vivo Characteristics:

Pulsatile, laminar & turbulent flow, bifurcating flow, not straight flow



Model flow:

Steady, laminar flow of a fluid in a straight, smooth, rigid, circular pipe



Velocity

$$v(r) = \frac{d^2 \Delta P}{16 \mu L} \left[1 - \left(\frac{r}{R_0} \right)^2 \right]$$


- **Parabolic** velocity profile
- Center velocity \gg Near-wall velocity
- No-slip boundary condition

Flow Rate

$$Q = \frac{\pi d^4 \Delta P}{128 \mu L} \quad \text{Poiseuille's law}$$

- $Q \sim d^4$ (d) = lumen inner diameter
- $Q \sim 1/\mu$ (μ) = blood viscosity

Hemodynamics (2)



Pressure (P)


A flow energy to drive fluid
to move through vessel

- unit: [Pa] or [mmHg]
- same as that of **stress**
(in fact, pressure is a **normal stress**)


Shear Stress (τ)

- a frictional force on the wall
in opposite direction of flow

$$\tau = \mu \frac{dv}{dr}$$



High Shear-induced Thrombosis



1. Mass Conservation

$$Q = A_1 V_1 = A_2 V_2 = \text{const}$$

$-V_2$: increase with $1/d^2$




2. Bernoulli's Law

$$\frac{p_1}{\rho} + \frac{1}{2} V_1^2 = \frac{p_2}{\rho} + \frac{1}{2} V_2^2 = \text{const}$$


$-P_2$: decreases (*spasm* may occur)

3. Shear stress $\sim (1/d)^3$


$$\tau = \frac{32\mu Q}{\pi d^3}$$




Vulnerable (Pro-thrombotic) blood




Shear induced Platelet Activation (SiPA)




Shear- Induced Platelet Activation



Whole Blood





Platelet Rich Plasma (PRP)





Stirrer-Induced Secondary flow

(a) narrow bar




(b) wide bar




- Spiral downward flow
 - Efficient mixing and
 - Homogeneous activation
- (Biomicrofluidics 2016)


(c)




(d)




Shear- Induced Platelet Activation





Migration Ratio (MR)



The higher shear,





the shorter distance.



$$MR = \frac{y}{Y}$$


Biomicrofluidics (2013)

Platelet activation test with FACS





Shear-induced Platelet Adhesion

w/o SIPA



SIPA




- Collagen caused adhesion of platelets.
- Secreted granules caused platelet aggregation.
- Adhesion & Aggregation of platelets result in flow stoppage.

Microfluidic platform


1 Shearing/Mixing

- rotational Couette flow
- Stirrer rotation
- high shear ($\tau > 8 \text{ Pa}$)
- efficient mixing



2 Agonist coating

- Microbeads in a chamber
- increased surface area
- Collagen or Fibrinogen




3 Migration-distance

- video-image processing
- Blood migration distance
- Flow rate : $Q=A(dl/dt)$




(a)





Collagen coated
Sample chamber
Shearing stirrer

(b)








(c)




Patent : US 004780418A, US 005051239A

Shin et al (Biomicrofluidics, 2013)

Adhesion & Aggregation



Effect of Collagen-Coating





	Activated Sample	Control
BSA-coated surface		
Collagen-coated		


On a **BSA coated surface**, any platelets did not adhere on the surface, whereas lots of platelets and aggregates were observed **on collagen surface**.

Minimum time for SIPA


Shearing
 $\Delta t = 5 - 10 \text{ s}$



Aggregation time
 $\Delta t = 0 \text{ min}$




Aggregation time
 $\Delta t = 1 \text{ min}$






- 5 - 10 s shearing time was **sufficient** to activate platelets.
- But, aggregation time was widely varied with samples. (20 s ~ 180 s)
- Therefore, we measure aggregation time until flow blockage.

Effect of Aspirin on SIPA




SIPA test on Aspirin sample

- ▶ Aspirin-treated samples ($n = 3$)
- ▶ Method: Shearing ($t = 30 \text{ s}$)
- ▶ Results:



Aspirin does not inhibit SIPA

5 Different Assays





- agonists
- coating

I. Bleeding Risk Screening

1. Collagen + Epinephrine (C-EPI)
2. Collagen + ADP (C-ADP)
3. SIPA test

II. Drug response Test


1. Aspirin test
2. P2Y12 test



Clinical Comparisons




PFA-200 (C-ADP) vs. AnySis (C-ADP)




장비간 비교임상 시험 (n = 72)


PFA-200 CADP vs. Multiplate analyzer




PFA-200 CADP vs. Plateletworks



Plateletworks vs. Multiplate analyzer



PFA-200 CADP vs. Anysis-CADP



- 동일 검사에 대한 장비간 비교임상 (n = 72명)
- 장비간의 상관성이 매우 낮음 ($r < 0.21$)

Anysis-ONE

I. 혈소판 검사 기기 (1등급) Anysis-ONE




II. 혈소판 복합기능 검사 칩 (3등급) RheoScan-PA1: COL/ADP

III. 항혈소판 약물반응 검사 칩 (3등급) RheoScan-PA2: Aspirin test



Conclusions

- **Shear stress at stenosed section** is significantly increased, proportional to $(1/d)^3$.
- Shear stress is a **strong agonistic factor** to activate platelets.
- SIPA requires relatively **short time ($t < 5$ s)** but sufficient shear stress ($t > 8$ Pa)
- **Aspirin cannot** inhibit SIPA and its consequences
- Clotted blood could be naturally lysed with tPA.
- Therefore, it may be required to test **thrombolysis** as well as **thrombosis**.



Acknowledgements



Collaborators (I)

- Kim, Yeul-Hong (M.D., Korea U) Clinical validation
- Kang, Jae-woo (Korea U.) : Big Data analysis
- Lee, Ho-Young (SNU): Drug Resistance
- Lee, Hyuk-jin (Ewha Women U.): Drug Delivery
- Lee, Jae-Seung (Korea Univ.): Nano plasmonics
- Na, Sung-soo (Korea U.) QCM sensor
- Han, Chang-Soo (Korea U.) Nano-patterning
- Park, KyungWha (Korea U) Clinical validation
- Bong, Ki-Wan (Korea U) : Flow Lithography
- Lee, WonJong (Incheon U) : Exosome
- Kim, SungJin (Konkuk U) : Microfluidics

Lab Members

Dr. Jang, Dae-Ho
 Na, Won-whi
 Seo, Changduck
 Lee, Ho-yoon
 Kim, Yeon-soo
 Kim, Geyhu
 Park, Sera
 Nam, Dongwoo
 Kim, Jin-Sung
 Han, Sung-Jae
 Kim, Namjoon
 Kwon, Seunghyun
 Han, HyoJung

Financial supports

- **NRF_nanoBiofluid Biopsy ERC (I)**
 (나노 생체유체생검 선도연구센터)
- KHIDI_Future Medical Device center (II)

Collaborators (II)

- Lim, Chae-Seung (MD, KU Guro Hospital)
- Lee, Byoung-Kown (MD, Yeosei U. Hospital)
- Lee, Kyung-Ah (MD, Yeosei U. Hospital)

